Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Robert Gordon

Psychiatry Upland, CA Medical Doctor

NPI 1528041654 CMS profile 68509

954 W Foothill Blvd, Suite A, Upland, CA 91786

Open in the dashboard

General payments

$3,308

215 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Robert Gordon of Upland, CA is reported in the CMS Open Payments database as having received $3,308 across 215 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $398 27
2021 General $793 50
2020 General $981 56
2019 General $1,136 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Gordon
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Robert Gordon were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Robert Gordon Psychiatry median Middle half National median
2019 $1,136 $184 $59–$605 $163
2020 $981 $119 $36–$372 $114
2021 $793 $143 $43–$576 $132
2022 $398 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Takeda Pharmaceuticals U.S.A., Inc. $568 33 payments
  2. Sunovion Pharmaceuticals Inc. $512 47 payments
  3. Otsuka America Pharmaceutical, Inc. $380 27 payments
  4. Lundbeck LLC $359 23 payments
  5. Vanda Pharmaceuticals Inc. $321 14 payments
  6. Ironshore Pharmaceuticals Inc. $164 6 payments
  7. Bausch Health US, LLC $146 7 payments
  8. Allergan Inc. $124 16 payments
  9. ITI, Inc. $124 7 payments
  10. Adlon Therapeutics L.P. $110 7 payments
  11. Other $498 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,308 215 payments
Products named General payments · program years 2019–2022
  1. LATUDA $512 47 payments
  2. REXULTI Psychiatry $380 27 payments
  3. TRINTELLIX $379 21 payments
  4. HETLIOZ $321 14 payments
  5. FANAPT $321 14 payments
  6. REXULTI Psychiatry $218 15 payments
  7. APLENZIN $146 7 payments
  8. Jornay PM 20mg capsules (Bottle of 100) $135 4 payments
  9. VRAYLAR $124 16 payments
  10. CAPLYTA $124 7 payments
  11. Other $1,391 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

215 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record